Biotech Values

[WorstLuck]

Financing and marketing.

General market conditions just haven't helped and can't be counted upon for a raise next year. The go-it-alone route would likely be more expensive in terms of dilution and time than many are expecting (even if the end result is still satisfying) absent unforeseen early and expanding sales. The launch is always hard for a small company and should be expected to be slower and more costly than plan.

Some additional licensing or partnership that serves the financing end well while contributing to the marketing, whatever region(s) covered, looks best for maximizing long term value.

A buyout prior to approval and label is possible but appears quite unlikely given market conditions and what the board might consider an acceptable price (best guess.)